[go: up one dir, main page]

PE20131141A1 - Anticuerpo monoclonal - Google Patents

Anticuerpo monoclonal

Info

Publication number
PE20131141A1
PE20131141A1 PE2013000112A PE2013000112A PE20131141A1 PE 20131141 A1 PE20131141 A1 PE 20131141A1 PE 2013000112 A PE2013000112 A PE 2013000112A PE 2013000112 A PE2013000112 A PE 2013000112A PE 20131141 A1 PE20131141 A1 PE 20131141A1
Authority
PE
Peru
Prior art keywords
amylomended
peptides
antibody
seq
amylohermede
Prior art date
Application number
PE2013000112A
Other languages
English (en)
Inventor
Andrea Pfeifer
Maria Pihlgren
Andreas Muhs
Ryan Watts
Original Assignee
Ac Immune Sa
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39790376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131141(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ac Immune Sa, Genentech Inc filed Critical Ac Immune Sa
Publication of PE20131141A1 publication Critical patent/PE20131141A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL QUE INCLUYE CUALQUIER ANTICUERPO FUNCIONALMENTE EQUIVALENTE O SUS PARTES FUNCIONALES, QUE RECONOCE UN EPITOPE CONFORMACIONAL, Y QUE SE UNE A PEPTIDOS Aß AMILOIDES SOLUBLES POLIMERICOS Y A PEPTIDOS Aß AMILOIDES OLIGOMERICOS QUE COMPRENDEN UNA PLURALIDAD DE PEPTIDOS Aß1-42 MONOMERICOS. DICHO ANTICUERPO COMPRENDE UN DOMINIO VARIABLE DE CADENA PESADA Y DE CADENA LIVIANA QUE EXHIBE UNA SECUENCIA DE AMINOACIDOS QUE ES DE 85% A 99% IDENTICAS A LA SEQ ID Nº7 Y SEQ ID Nº 8, O UNA PARTE FUNCIONAL DE ESTA QUE COMPRENDE UNA PARTE O LA TOTALIDAD DE LAS CDR DE CADENA LIVIANA Y DE CADENA PESADA QUE CONTIENEN LAS SECUENCIAS DE POLIPEPTIDOS SEQ ID Nº 9-14. SE REFIERE TAMBIEN A UN METODO DE PRODUCCION Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO SIENDO UTIL PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS CAUSADOS O ASOCIADOS A LAS PROTEINAS AMILOIDES O SIMILARES QUE INCLUYEN LA AMILOIDOSIS, ENFERMEDAD DE ALZHEIMER, SINDROME DE DOWN.
PE2013000112A 2007-06-12 2008-06-12 Anticuerpo monoclonal PE20131141A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94354107P 2007-06-12 2007-06-12
US94354307P 2007-06-12 2007-06-12
US94379007P 2007-06-13 2007-06-13

Publications (1)

Publication Number Publication Date
PE20131141A1 true PE20131141A1 (es) 2013-10-14

Family

ID=39790376

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008001009A PE20090831A1 (es) 2007-06-12 2008-06-12 Anticuerpo monoclonal
PE2013000112A PE20131141A1 (es) 2007-06-12 2008-06-12 Anticuerpo monoclonal

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008001009A PE20090831A1 (es) 2007-06-12 2008-06-12 Anticuerpo monoclonal

Country Status (18)

Country Link
EP (2) EP2170953B1 (es)
JP (2) JP5436414B2 (es)
KR (2) KR101600095B1 (es)
CN (1) CN101802007B (es)
AR (1) AR066987A1 (es)
AU (1) AU2008267037B2 (es)
BR (1) BRPI0812484A2 (es)
CA (1) CA2690434C (es)
CL (3) CL2008001742A1 (es)
ES (1) ES2548102T3 (es)
IL (1) IL202563A (es)
MX (1) MX2009013503A (es)
NZ (2) NZ581835A (es)
PE (2) PE20090831A1 (es)
RU (1) RU2571856C2 (es)
TW (2) TWI453217B (es)
WO (1) WO2008156621A1 (es)
ZA (1) ZA201000049B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
TWI453217B (zh) * 2007-06-12 2014-09-21 Ac Immune Sa 抗β類澱粉蛋白單株抗體
SG10201505369QA (en) * 2007-10-05 2015-08-28 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
MX2012009460A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Int Polipeptidos biparatopicos de union abeta.
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
KR101713365B1 (ko) 2010-07-30 2017-03-08 에이씨 이뮨 에스.에이. 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
SI2646470T1 (sl) 2010-11-30 2017-05-31 F. Hoffmann-La Roche Ag Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade
CN103443277B (zh) 2011-02-18 2016-02-24 国立大学法人东京农工大学 淀粉样蛋白低聚物结合核酸适体
WO2013020372A1 (zh) * 2011-08-09 2013-02-14 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
CA2811188C (en) * 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
JP6612214B2 (ja) 2013-05-20 2019-11-27 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法
SG10201802525QA (en) 2013-09-13 2018-04-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
EP3044323B1 (en) 2013-09-13 2022-04-06 F. Hoffmann-La Roche AG Methods for detecting and quantifying host cell protein in cell lines
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
JP6861418B2 (ja) 2015-09-02 2021-04-28 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド ヒトｔ細胞免疫グロブリン及びｉｔｉｍドメイン（ｔｉｇｉｔ）に特異的な抗体
JP7452829B2 (ja) 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
JP6994469B2 (ja) * 2016-04-20 2022-02-04 エアラン セル テクノロジーズ， インコーポレイテッド Ｋ１８０ジメチル化ｈ１．０タンパク質に関連する組成物および方法
AU2017299858B2 (en) 2016-07-18 2024-07-25 Promis Neurosciences, Inc. Antibodies to Amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
WO2020025066A1 (en) * 2018-08-03 2020-02-06 The University Of Hong Kong Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, rna, and nucleoli
KR101977410B1 (ko) * 2018-08-22 2019-05-10 주식회사 피플바이오 당뇨병에 대한 신규 바이오마커 및 그의 용도
US12016885B2 (en) 2018-11-06 2024-06-25 Alsatech, Inc. Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
CN111518205B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN111518206B (zh) 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
EP3757125A1 (en) * 2019-06-28 2020-12-30 BioArctic AB Antibody directed against the apoe amino-terminal fragment of 12 kda
CN110317814A (zh) * 2019-07-19 2019-10-11 莫丁丁 β-淀粉样蛋白环状核糖核酸、多肽及其应用
WO2021048324A1 (en) * 2019-09-10 2021-03-18 Ac Immune Sa Novel molecules for diagnosis
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
CN110687035A (zh) * 2019-10-10 2020-01-14 沈阳万类生物科技有限公司 Annexin V-Light 650凋亡检测试剂盒
CN113884683A (zh) * 2020-07-30 2022-01-04 山东京济生物工程有限公司 一种快速检测Aβ42的双抗体夹心ELISA试剂盒
CN113308439B (zh) * 2020-11-06 2023-05-05 华中科技大学 分泌人淀粉样蛋白-β单克隆抗体的杂交瘤细胞株及其应用
CN112540180B (zh) * 2020-11-06 2022-03-29 华中科技大学 用于检测人淀粉样蛋白-β双抗夹心ELISA检测试剂盒
CN113057963B (zh) * 2021-03-31 2022-05-20 华中科技大学 一种用于清除β-淀粉样蛋白的特异性捕获载体及其应用
CN113311153B (zh) * 2021-05-12 2023-05-26 华中科技大学 一种用于阿尔茨海默病诊疗一体化的多功能的纳米粒子
CN113603773B (zh) * 2021-08-17 2023-05-09 中国医科大学附属第一医院 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
KR102565470B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 sma_04088-2 및 이를 포함하는 알츠하이머병 치료용 조성물
KR102565471B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 cbrv1-04369 및 이를 포함하는 알츠하이머병 치료용 조성물
CN117586370A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体及其用途
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
CN119390832A (zh) * 2024-10-12 2025-02-07 中国科学技术大学 一种兔源Aβ 1-40单克隆抗体、制备方法及应用
CN120098147B (zh) * 2025-05-07 2025-07-15 中山大学 一种纳米自组装抗Aβ抗体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20030229208A1 (en) * 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
EP0652775B1 (en) 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targeting of liposomes to the blood-brain barrier
ZA938243B (en) * 1992-11-12 1995-05-04 Hybritech Inc Altered affinity polypeptides of metal chelate binding antibodies
CA2127476C (en) 1994-07-06 1999-12-07 Daniel G. Pomerleau Logging or measurement while tripping
AU702436B2 (en) 1994-10-21 1999-02-18 Innogenetics N.V. New sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
WO1997010505A1 (en) * 1995-09-14 1997-03-20 The Regents Of The University Of California ANTIBODIES SPECIFIC FOR NATIVE PrP?Sc¿
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP1420032B2 (en) * 2001-08-03 2015-12-16 Medical & Biological Laboratories Co., Ltd. Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody
CN100488982C (zh) * 2001-11-02 2009-05-20 迪尔基因国际有限公司 与β-淀粉样蛋白结合并引起蛋白质构象转变的单克隆抗体的制备方法
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7220833B2 (en) 2002-12-03 2007-05-22 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
EA012325B1 (ru) 2002-12-24 2009-08-28 Беллус Хелс (Интернэшнл) Лимитед Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
WO2004065569A2 (en) * 2003-01-23 2004-08-05 The Regents Of The University Of California Multi-functional antibodies
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
JP4870348B2 (ja) * 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス 細胞表面抗原に対する抗体取得とその抗原同定
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
EP2269633A1 (en) 2005-05-05 2011-01-05 Merck Sharp & Dohme Corp. Peptide conjugate compositions and methods for the prevention and treatment of Alzheimer's disease
EP2594591B1 (en) * 2005-08-11 2018-06-06 Arpi Matossian-Rogers Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease
AU2006301492B2 (en) * 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
EP1976877B2 (en) * 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
TWI453217B (zh) * 2007-06-12 2014-09-21 Ac Immune Sa 抗β類澱粉蛋白單株抗體

Also Published As

Publication number Publication date
EP2527366A1 (en) 2012-11-28
BRPI0812484A2 (pt) 2018-06-05
PE20090831A1 (es) 2009-07-10
KR20160017126A (ko) 2016-02-15
RU2010100354A (ru) 2011-07-20
JP2010530227A (ja) 2010-09-09
JP5436414B2 (ja) 2014-03-05
KR101600095B1 (ko) 2016-03-07
CN101802007B (zh) 2017-08-25
HK1140500A1 (en) 2010-10-15
EP2170953B1 (en) 2015-07-15
NZ601843A (en) 2014-01-31
CL2012001817A1 (es) 2012-12-14
ZA201000049B (en) 2018-11-28
TWI453217B (zh) 2014-09-21
WO2008156621A1 (en) 2008-12-24
CL2008001742A1 (es) 2008-11-21
NZ581835A (en) 2012-09-28
ES2548102T3 (es) 2015-10-13
TWI516500B (zh) 2016-01-11
CL2012000631A1 (es) 2012-10-05
RU2571856C2 (ru) 2015-12-20
AU2008267037B2 (en) 2014-08-07
MX2009013503A (es) 2010-01-27
KR20100027216A (ko) 2010-03-10
EP2527366B1 (en) 2017-08-16
EP2170953A1 (en) 2010-04-07
TW200906852A (en) 2009-02-16
CN101802007A (zh) 2010-08-11
CA2690434C (en) 2018-05-22
IL202563A (en) 2016-05-31
JP2014087353A (ja) 2014-05-15
IL202563A0 (en) 2011-08-01
TW201441256A (zh) 2014-11-01
CA2690434A1 (en) 2008-12-24
AR066987A1 (es) 2009-09-23
AU2008267037A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
PE20131141A1 (es) Anticuerpo monoclonal
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
AR069130A1 (es) Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
PE20171512A1 (es) Anticuerpos anti-fap
AR110751A1 (es) Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con proteínas de unión al receptor del péptido inhibidor gástrico (gipr)
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
EA202190264A1 (ru) КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
EA200970694A1 (ru) ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ
PE20090359A1 (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
PE20250415A1 (es) Composiciones y metodos de inhibicion del masp-3 para el tratamiento de diversas enfermedades y trastornos
BR112022009273A2 (pt) Imunoglobulinas modificadas para direcionar depósitos amiloides
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
BR112016030686A2 (pt) anticorpos anti tau humanizados
GEP20115324B (en) Tweak binding antibodies
PE20140231A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
AR083672A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
JP2016531546A5 (es)
FI3452507T3 (fi) Tau-immuunihoito
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител

Legal Events

Date Code Title Description
FG Grant, registration